{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:00:10Z","timestamp":1760644810753},"reference-count":136,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[1995,3,1]],"date-time":"1995-03-01T00:00:00Z","timestamp":794016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[1995,3]]},"DOI":"10.1016\/0305-7372(95)90023-3","type":"journal-article","created":{"date-parts":[[2004,5,25]],"date-time":"2004-05-25T16:39:07Z","timestamp":1085503147000},"page":"105-132","source":"Crossref","is-referenced-by-count":66,"title":["High-dose chemotherapy regimens for solid tumors"],"prefix":"10.1016","volume":"21","author":[{"given":"E.","family":"van der Wall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rodenhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/0305-7372(95)90023-3_BIB1","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1200\/JCO.1993.11.6.1132","article-title":"High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer","volume":"11","author":"Peters","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB2","first-page":"76","article-title":"Intensive chemotherapy with autologous bone marrow reinfusion in patients with breast cancer and more than 5 involved lymph nodes","volume":"12","author":"Mulder","year":"1993"},{"key":"10.1016\/0305-7372(95)90023-3_BIB3","first-page":"93","article-title":"Consolidation for high risk breast cancer with high dose chemotherapy and autologous bone marrow rescue","volume":"13","author":"Overmoyer","year":"1994"},{"key":"10.1016\/0305-7372(95)90023-3_BIB4","series-title":"Educational book of the American Society of Clinical Oncology","first-page":"74","article-title":"High-dose consolidation for stage IV breast cancer","author":"Livingston","year":"1994"},{"key":"10.1016\/0305-7372(95)90023-3_BIB5","series-title":"European Group for Bone Marrow Transplantation, Working Party Solid Tumor Registry","first-page":"94","article-title":"Breast carcinoma: 203 patients","author":"Philip","year":"1993"},{"key":"10.1016\/0305-7372(95)90023-3_BIB6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.1994.12.1.226","article-title":"Consensus conference on intensive chemotherapy plus hematopoietic stem-cell transplantation in malignancies: Lyon, France, June 4\u20136, 1993","volume":"12","author":"Coiffier","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB7","first-page":"1247","article-title":"Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation","volume":"68","author":"Sladek","year":"1984","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/0305-7372(95)90023-3_BIB8","first-page":"1121","article-title":"Alkylating properties of phosphoramide mustard","volume":"36","author":"Colvin","year":"1976","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB9","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/0006-2952(79)90222-3","article-title":"Cyclophosphamide cystitis-identification of acrolein as the causative agent","volume":"28","author":"Cox","year":"1979","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00686337","article-title":"A phase I trial of continuous-infusion cyclophosphamine in refractory cancer patients","volume":"29","author":"Eder","year":"1991","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB11","first-page":"120","article-title":"Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation","volume":"76","author":"Fasola","year":"1991","journal-title":"Haematologica"},{"key":"10.1016\/0305-7372(95)90023-3_BIB12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/BF00255760","article-title":"Decreased plasma half-life of cyclophosphamide during repeated high-dose administration","volume":"10","author":"Graham","year":"1983","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB13","first-page":"226","article-title":"Clinical pharmacology of cyclophosphamide","volume":"33","author":"Bagley","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB14","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2165\/00003088-197904050-00004","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"4","author":"Grochow","year":"1978","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/0305-7372(95)90023-3_BIB15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-199120030-00002","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"20","author":"Moore","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/0305-7372(95)90023-3_BIB16","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood.V68.5.1114.1114","article-title":"Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor","volume":"68","author":"Goldberg","year":"1986","journal-title":"Blood"},{"key":"10.1016\/0305-7372(95)90023-3_BIB17","first-page":"128","article-title":"Hemorrhagic cystitis complicating bone marrow transplantation","volume":"67","author":"Letendre","year":"1992"},{"key":"10.1016\/0305-7372(95)90023-3_BIB18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/bjc.1984.252","article-title":"Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study","volume":"50","author":"Hows","year":"1984","journal-title":"Br. J. Cancer"},{"key":"10.1016\/0305-7372(95)90023-3_BIB19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/mpo.2950080312","article-title":"Studies of the antidiuretic effect of cyclophosphamide","volume":"8","author":"Bode","year":"1980","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB20","first-page":"517","article-title":"Ifosfamide metabolism and pharmacokinetics (Review)","volume":"14","author":"Kaijser","year":"1994","journal-title":"Anticancer Res."},{"issue":"Suppl 4","key":"10.1016\/0305-7372(95)90023-3_BIB21","first-page":"68","article-title":"Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules","volume":"17","author":"Antman","year":"1990","journal-title":"Semin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1200\/JCO.1990.8.1.170","article-title":"High-dose ifosfamide with mesna uroprotection: a phase I study","volume":"8","author":"Elias","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB23","series-title":"Seventh Cain Memorial Award lecture","first-page":"1","article-title":"Oxazaphosphorine cytostatics: past-present-future","volume":"49","author":"Brock","year":"1989"},{"key":"10.1016\/0305-7372(95)90023-3_BIB24","first-page":"14","article-title":"Ifosfamide in experimental tumor systems","volume":"9","author":"Goldin","year":"1982","journal-title":"Semin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood.V60.3.693.693","article-title":"IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy","volume":"60","author":"Cabanillas","year":"1982","journal-title":"Blood"},{"key":"10.1016\/0305-7372(95)90023-3_BIB26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.1989.7.1.126","article-title":"Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma","volume":"7","author":"Antman","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB27","first-page":"1311","article-title":"The analysis of ifosfamide and its metabolites (review)","volume":"13","author":"Kaijser","year":"1993","journal-title":"Anticancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB28","series-title":"High-dose cancer therapy","first-page":"54","article-title":"Pharmacokinetics","author":"Jones","year":"1992"},{"key":"10.1016\/0305-7372(95)90023-3_BIB29","first-page":"242","article-title":"Cisplatin","author":"Cvitkovic","year":"1993"},{"key":"10.1016\/0305-7372(95)90023-3_BIB30","first-page":"509","article-title":"Plasma levels and urinary excretion of filterable cisplatinum species following bolus injection and IV infusion of cisdichlorodiammineplatinum(II) in man","volume":"66","author":"Patton","year":"1982","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/0305-7372(95)90023-3_BIB31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00263904","article-title":"Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammineplatinum(II)","volume":"15","author":"Reece","year":"1985","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB32","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/1097-0142(197804)41:4<1274::AID-CNCR2820410410>3.0.CO;2-F","article-title":"Long term effect of cisdiamminechloride platinum (CDDP) on renal function and structure in man","volume":"41","author":"Dentino","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/0305-7372(95)90023-3_BIB33","doi-asserted-by":"crossref","first-page":"628","DOI":"10.7326\/0003-4819-95-5-628","article-title":"Renal and electrolyte disturbances associated with cisplatin","volume":"95","author":"Blachly","year":"1981","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/0305-7372(95)90023-3_BIB34","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1200\/JCO.1991.9.7.1163","article-title":"Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a southeastern cancer study group and southwest oncology group protocol","volume":"9","author":"Nichols","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB35","first-page":"19","article-title":"Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration","volume":"66","author":"Reddel","year":"1982","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/0305-7372(95)90023-3_BIB36","series-title":"Carboplatin (JM-8), Current Perspectives and Future Directions","first-page":"19","article-title":"Pharmacologic characteristics of carboplatin: clinical experience","author":"Canetta","year":"1990"},{"key":"10.1016\/0305-7372(95)90023-3_BIB37","first-page":"1972","article-title":"Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA","volume":"46","author":"Knox","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/BF00257742","article-title":"Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II","volume":"9","author":"Calvert","year":"1982","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"Suppl 5","key":"10.1016\/0305-7372(95)90023-3_BIB39","first-page":"1","article-title":"The pharmacology of carboplatin","volume":"16","author":"Van Echo","year":"1989","journal-title":"Semin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB40","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB41","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.1989.7.5.651","article-title":"A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support","volume":"7","author":"Shea","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB42","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/BF00686244","article-title":"Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study","volume":"25","author":"Vlasveld","year":"1990","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"Suppl 5","key":"10.1016\/0305-7372(95)90023-3_BIB43","first-page":"7","article-title":"Overview of carboplatin: replacing, complementing and extending the therapeutic horizons of cisplatin","volume":"16","author":"Muggia","year":"1989","journal-title":"Semin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB44","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/0277-5379(87)90125-8","article-title":"High-dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study","volume":"23","author":"Gore","year":"1987","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB45","first-page":"4996","article-title":"Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N\u2032,N\u2033-Triethylenethiophosphoramide","volume":"49","author":"Teicher","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB46","first-page":"4360","article-title":"Interaction of N,N\u2032,N\u2033-Triethylenethiophosphoramide and N,N\u2032,N\u2033-Triethylenephosphoramide with cellular DNA","volume":"51","author":"Cohen","year":"1991","journal-title":"Cancer Res."},{"issue":"Suppl 3","key":"10.1016\/0305-7372(95)90023-3_BIB47","first-page":"7","article-title":"Cellular transport and accumulation of thiotepa","volume":"17","author":"Egorin","year":"1990","journal-title":"Semin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB48","first-page":"1265","article-title":"Plasma pharmacokinetics and tissue distribution of thiotepa in mice","volume":"68","author":"Egorin","year":"1984","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/0305-7372(95)90023-3_BIB49","first-page":"3171","article-title":"Phase I pharmacokinetic reevaluation of ThioTEPA","volume":"51","author":"O'Dwyer","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB50","series-title":"High-dose Cancer Therapy","first-page":"55","article-title":"Pharmacokinetics","author":"Jones","year":"1992"},{"key":"10.1016\/0305-7372(95)90023-3_BIB51","first-page":"859","article-title":"Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites","volume":"70","author":"Cohen","year":"1986","journal-title":"Cancer Treat. Rep."},{"issue":"Suppl 3","key":"10.1016\/0305-7372(95)90023-3_BIB52","first-page":"2","article-title":"High-dose N,N\u2032,N\u2033-Triethylenethiophosphoramide (Thiotepa) with autologous bone marrow transplantation: phase I studies","volume":"17","author":"Wolff","year":"1990","journal-title":"Semin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB53","first-page":"250","article-title":"Nitrosureas: Pharmacologic overview","author":"Damia","year":"1993"},{"key":"10.1016\/0305-7372(95)90023-3_BIB54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0006-2952(90)90645-2","article-title":"Mechanism of action of the nitrosureas-IV synthesis of the 2-haloethylnitrosurea-induced DNA cross-link 1-(3-citosinyl), 2(guanyl)ethane","volume":"39","author":"MacFarland","year":"1990","journal-title":"Biochem. Pharm."},{"key":"10.1016\/0305-7372(95)90023-3_BIB55","first-page":"6119","article-title":"Mammalian 06-alkylguanine-DNA-alkyltransferase: regulation and importance in response to alkylating carcinogenetic and therapeutic agents","volume":"50","author":"Pegg","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB56","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/288727a0","article-title":"DNA cross-linking and monoadduct repair in nitrosurea-treated human tumor cells","volume":"288","author":"Erickson","year":"1980","journal-title":"Nature"},{"key":"10.1016\/0305-7372(95)90023-3_BIB57","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0305-7372(88)90026-6","article-title":"Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy","volume":"15","author":"D'Incalci","year":"1988","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/0305-7372(95)90023-3_BIB58","first-page":"877","article-title":"Pharmacokinetics and immediate effects of high-dose carmustine in man","volume":"70","author":"Henner","year":"1986","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/0305-7372(95)90023-3_BIB59","first-page":"31","article-title":"Contributions of nitrosureas to cancer treatment","volume":"70","author":"Mitchell","year":"1986","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/0305-7372(95)90023-3_BIB60","series-title":"A phase I\u2013II study","first-page":"1792","article-title":"Intensive 1,3-bis(2-chloroethyl)-1-nitrosurea (BCNU), NSC#4366650 and cryopreserved autologous marrow transplantation for refractory cancer","volume":"52","author":"Philips","year":"1983"},{"key":"10.1016\/0305-7372(95)90023-3_BIB61","first-page":"1257","article-title":"High-dose BCNU therapy with autologous bone marrow infusion: preliminary observations","volume":"63","author":"Spitzer","year":"1979","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/0305-7372(95)90023-3_BIB62","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJM199008093230604","article-title":"Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood","volume":"323","author":"O'Driscoll","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/0305-7372(95)90023-3_BIB63","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00001813-199012000-00002","article-title":"Mitoxantrone: bluebeard for malignancies","volume":"1","author":"Van der Graff","year":"1990","journal-title":"AntiCancer Drugs"},{"key":"10.1016\/0305-7372(95)90023-3_BIB64","first-page":"4915","article-title":"Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene","volume":"45","author":"Bowden","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB65","first-page":"671","article-title":"Action of dihyroxyanthraquinone on cell cycle progression and survival of a variety of cultured mammalian cells","volume":"40","author":"Traganos","year":"1980","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB66","doi-asserted-by":"crossref","first-page":"67","DOI":"10.7326\/0003-4819-105-1-67","article-title":"Mitoxantrone: a new anticancer drug with significant clinical activity","volume":"105","author":"Shenkenberg","year":"1986","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/0305-7372(95)90023-3_BIB67","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage is mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"issue":"Suppl 1","key":"10.1016\/0305-7372(95)90023-3_BIB68","first-page":"3","article-title":"Biologic and biochemical effects of mitoxantrone","volume":"11","author":"Durr","year":"1984","journal-title":"Semin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB69","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF00292881","article-title":"Pharmacology of mitoxantrone in cancer patients","volume":"8","author":"Savaraj","year":"1982","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB70","first-page":"1879","article-title":"Disposition of mitoxantrone in cancer patients","volume":"45","author":"Alberts","year":"1985","journal-title":"Cancer Res."},{"issue":"Suppl 3","key":"10.1016\/0305-7372(95)90023-3_BIB71","first-page":"43","article-title":"Mitoxantrone: potential for use in intensive therapy","volume":"1","author":"Lemaistre","year":"1990","journal-title":"Semin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB72","first-page":"1516","article-title":"Phase I clinical investigation of 1,4-dihydroxy-5,8-bis{{{2-[2-hydroxyethyl)ami ethyl}amino}}-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione","volume":"40","author":"Von Hoff","year":"1980","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB73","first-page":"4654","article-title":"High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors","volume":"49","author":"Mulder","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB74","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/0277-5379(84)90122-6","article-title":"Mitoxantrone for the treatment of advanced breast cancer: single agent therapy in previously untreated patients","volume":"20","author":"Cornbleet","year":"1984","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB75","series-title":"High-dose Cancer Therapy, Pharmacology, Hematopoietins, Stem Cells","first-page":"52","article-title":"Pharmacokinetics","author":"Jones","year":"1992"},{"key":"10.1016\/0305-7372(95)90023-3_BIB76","first-page":"5397","article-title":"Melphalan transport, glutathione levels and gluthatione-S-transferase activity in human medulloblastoma","volume":"48","author":"Friedman","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB77","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00273524","article-title":"High-dose melphalan dosage adjustment: possibility of using a test-dose","volume":"23","author":"Tranchand","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB78","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0014-2964(78)90253-0","article-title":"Pharmacokinetics of melphalan following oral or intravenous administration in patients with malignant disease","volume":"14","author":"Tattersall","year":"1978","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/0305-7372(95)90023-3_BIB79","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/bjc.1983.196","article-title":"Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation","volume":"48","author":"Cornbleet","year":"1983","journal-title":"Br. J. Cancer"},{"key":"10.1016\/0305-7372(95)90023-3_BIB80","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(78)92529-1","article-title":"Acceleration of bone marrow recovery by pretreatment with cyclophosphamide in patients receiving high-dose melphalan","volume":"11","author":"Hedley","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/0305-7372(95)90023-3_BIB81","first-page":"101","article-title":"The chemical and biological properties of busulphan (myleran)","volume":"2","author":"Dun","year":"1974","journal-title":"Exp. Hematol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB82","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/BF00558081","article-title":"Pharmacokinetics and metabolic studies of high-dose busulphan in adults","volume":"36","author":"Hassan","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB83","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00694339","article-title":"Pharmacokinetics of busulphan: correlation with veno-occlusive disease in patients under-going bone marrow transplantation","volume":"25","author":"Grochow","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB84","first-page":"1795","article-title":"Clinical pharmacokinetics and pharmacodynamics of anticancer agents in pediatric patients (review)","volume":"13","author":"Knoester","year":"1993","journal-title":"Anticancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB85","first-page":"229","article-title":"Alkylating agents: cyclophosphamide, ifosfamide, melphalan, thiotepa, chroambucil, busulfan","author":"Vassal","year":"1993"},{"key":"10.1016\/0305-7372(95)90023-3_BIB86","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003088-198712040-00001","article-title":"The clinical pharmacology of etoposide and teniposide","volume":"12","author":"Clark","year":"1987","journal-title":"Clin. Pharmacokin."},{"key":"10.1016\/0305-7372(95)90023-3_BIB87","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1200\/JCO.1984.2.3.215","article-title":"Penetration of VP 16\u2013213 into cerebrospinal fluid after high-dose intravenous administration","volume":"2","author":"Postmus","year":"1984","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB88","first-page":"1471","article-title":"High-dose etoposide for refractory malignancies: A phase I study","volume":"68","author":"Postmus","year":"1984","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/0305-7372(95)90023-3_BIB89","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1200\/JCO.1993.11.8.1602","article-title":"Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer","volume":"11","author":"Minami","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB90","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.1993.11.6.1080","article-title":"Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease","volume":"11","author":"Hudson","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB91","first-page":"1354","article-title":"Pharmacology of Mitomycin C: I: toxicity and pathologic effects","volume":"20","author":"Philips","year":"1960","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB92","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0305-7372(76)80019-9","article-title":"Mitomycin C: a review","volume":"3","author":"Crooke","year":"1976","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/0305-7372(95)90023-3_BIB93","first-page":"5017","article-title":"Pharmacokinetics of Mitomycin C in humans","volume":"43","author":"Den Hartigh","year":"1983","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB94","first-page":"299","article-title":"Mitomycin C","author":"Beretta","year":"1993"},{"key":"10.1016\/0305-7372(95)90023-3_BIB95","first-page":"805","article-title":"Phase I\u2013II study of high-dose Mitomycin with autologous bone marrow transplantation in refractory metastatic breast cancer","volume":"68","author":"Tannir","year":"1984","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/0305-7372(95)90023-3_BIB96","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/1097-0142(19820501)49:9<1789::AID-CNCR2820490910>3.0.CO;2-H","article-title":"Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation","volume":"49","author":"Lazarus","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/0305-7372(95)90023-3_BIB97","first-page":"277","article-title":"Phase I study of high-dose mitomycin C with autologous bone marrow support","volume":"66","author":"Sarna","year":"1982","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/0305-7372(95)90023-3_BIB98","series-title":"Mechanisms of Drug Resistance in Neoplastic Cells","first-page":"69","article-title":"Resistance to alkylating agents: basic studies and therapeutic implications","author":"Frei","year":"1988"},{"key":"10.1016\/0305-7372(95)90023-3_BIB99","first-page":"6417","article-title":"Preclinical studies and clinical correlation of the effect of alkylating dose","volume":"48","author":"Frei","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB100","first-page":"94","article-title":"Combination of N,N\u2032,N\u2033-Triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo","volume":"48","author":"Teicher","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB101","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000401484","article-title":"Patterns of resistance and therapeutic synergism among alkylating agents","volume":"23","author":"Schabel","year":"1978","journal-title":"Antibiot. Chemother."},{"key":"10.1016\/0305-7372(95)90023-3_BIB102","series-title":"High-dose Cancer Therapy","first-page":"3","article-title":"Pharmacologic strategies for high-dose chemotherapy","author":"Frei","year":"1992"},{"key":"10.1016\/0305-7372(95)90023-3_BIB103","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO.1987.5.2.260","article-title":"A phase I\u2013II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer","volume":"5","author":"Williams","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB104","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/80.15.1221","article-title":"Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors","volume":"80","author":"Eder","year":"1988","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/0305-7372(95)90023-3_BIB105","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.1989.7.12.1824","article-title":"High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer","volume":"7","author":"Williams","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB106","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/jnci\/83.13.920","article-title":"High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer","volume":"83","author":"Kennedy","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/0305-7372(95)90023-3_BIB107","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00689576","article-title":"Influence of scheduling on two-drug combinations of alkylating agents in vivo","volume":"25","author":"Teicher","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"Suppl 3","key":"10.1016\/0305-7372(95)90023-3_BIB108","first-page":"33","article-title":"High-dose thiotepa alone and in combination regimens with bone marrow support","volume":"17","author":"Antman","year":"1990","journal-title":"Semin Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB109","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.1990.8.7.1239","article-title":"A phase I\u2013II study of cyclophosphamide, thiotepa and carboplatin with autologous bone marrow transplantation in solid tumor patients","volume":"8","author":"Eder","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.1992.10.1.102","article-title":"A phase II study of high-dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy","volume":"10","author":"Antman","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB111","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JCO.1994.12.1.37","article-title":"Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study","volume":"12","author":"Ayash","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB112","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/oxfordjournals.annonc.a058111","article-title":"Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, thiotepa and cyclophosphamide","volume":"3","author":"Rodenhuis","year":"1992","journal-title":"Ann. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB113","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.1995.165","article-title":"Highdose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach","author":"Van der Wall","year":"1995","journal-title":"Br. J. Cancer"},{"key":"10.1016\/0305-7372(95)90023-3_BIB114","doi-asserted-by":"crossref","DOI":"10.3109\/07357909509031915","article-title":"Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer","author":"Rodenhuis","year":"1995","journal-title":"Cancer Invest."},{"key":"10.1016\/0305-7372(95)90023-3_BIB115","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.1994.12.2.342","article-title":"Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation","volume":"12","author":"Ghalie","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB116","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1200\/JCO.1986.4.5.646","article-title":"High-dose combination alkylating agents with autologous bone marrow support: a phase I trial","volume":"4","author":"Peters","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB117","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1164\/ajrccm\/147.5.1264","article-title":"Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation","volume":"147","author":"Todd","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/0305-7372(95)90023-3_BIB118","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1200\/JCO.1986.4.11.1592","article-title":"High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer","volume":"4","author":"Eder","year":"1986","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB119","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1200\/JCO.1988.6.9.1368","article-title":"High-dose combination of alkylating agents with bone marrow support as initial treatment for metastatic breast cancer","volume":"6","author":"Peters","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB120","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1200\/JCO.1988.6.8.1314","article-title":"High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors","volume":"6","author":"Slease","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB121","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF02897264","article-title":"High-dose carboplatin, cyclophosphamide and BCNU with autologous bone marrow support: excessive hepatic toxicity","volume":"26","author":"Jones","year":"1990","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB122","series-title":"A dose escalation study","first-page":"777","article-title":"Cyclophosphamide and VP 16\u2013213 with autologous bone marrow transplantation","volume":"20","author":"Postmus","year":"1984"},{"key":"10.1016\/0305-7372(95)90023-3_BIB123","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.1987.5.12.1864","article-title":"Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study","volume":"5","author":"Humblet","year":"1987","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 2","key":"10.1016\/0305-7372(95)90023-3_BIB124","first-page":"139","article-title":"A dose-escalation study of carboplatin\/cyclophosphamide\/etoposide along with autologous bone marrow or peripheral blood stem cell rescue","volume":"19","author":"Shea","year":"1992","journal-title":"Semin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB125","first-page":"3730","article-title":"Phase I trial with pharmacokinetic analysis of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors","volume":"53","author":"Motzer","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/0305-7372(95)90023-3_BIB126","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.1989.7.7.932","article-title":"Dose-intensive chemotherapy in refractory germ cell cancer-a phase I\/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation","volume":"7","author":"Nichols","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB127","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.1992.10.4.558","article-title":"High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group Protocol","volume":"10","author":"Nicols","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB128","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/1097-0142(19911001)68:7<1513::AID-CNCR2820680708>3.0.CO;2-8","article-title":"Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors","volume":"68","author":"Broun","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/0305-7372(95)90023-3_BIB129","first-page":"53","article-title":"High-dose carboplatinNP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors","volume":"7","author":"Broun","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/0305-7372(95)90023-3_BIB130","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/oxfordjournals.annonc.a058100","article-title":"High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: a phase two study","volume":"3","author":"Rosti","year":"1992","journal-title":"Ann. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB131","first-page":"12","article-title":"The development of busulfan\/cyclophosphamide preparative regimens","volume":"20","author":"Santos","year":"1993","journal-title":"Semin. Oncol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB132","first-page":"337","article-title":"Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer","volume":"11","author":"Klumpp","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/0305-7372(95)90023-3_BIB133","first-page":"87","article-title":"Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer","volume":"14","author":"De Vries","year":"1994"},{"key":"10.1016\/0305-7372(95)90023-3_BIB134","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0167-5273(92)90024-W","article-title":"Cardiac complications of intensive dose mitoxantrone and cyclophosphamide with autologous bone marrow transplantation in metastatic breast cancer","volume":"34","author":"Lewkow","year":"1992","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/0305-7372(95)90023-3_BIB135","first-page":"525","article-title":"Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer","volume":"12","author":"Bowers","year":"1993","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/0305-7372(95)90023-3_BIB136","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00000421-199302000-00003","article-title":"High-dose carboplatin and mitoxantrone with autologous bone marrow support in the treatment of advanced breast cancer","volume":"16","author":"Broun","year":"1993","journal-title":"Am. J. Clin. Oncol. (CCT)"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0305737295900233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0305737295900233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T07:33:40Z","timestamp":1585812820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/0305737295900233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,3]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1995,3]]}},"alternative-id":["0305737295900233"],"URL":"https:\/\/doi.org\/10.1016\/0305-7372(95)90023-3","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[1995,3]]}}}